Screening for early signs of Parkinson's Disease
Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study
This study is trying to find early signs of Parkinson's Disease in people who might be at higher risk and will follow them for five years to learn more about how the disease develops.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 50 Years to 99 Years |
| Sex | All |
| Sponsor | University Hospital Schleswig-Holstein Academic / other |
| Locations | 1 site (Kiel) |
| Trial ID | NCT04724941 on ClinicalTrials.gov |
What this trial studies
The PASS-PD study aims to screen individuals at increased risk for developing Parkinson's Disease (PD) from the general population and follow them over five years. It focuses on understanding risk profiles, identifying individuals likely to develop PD, and exploring the role of biological markers in predicting disease progression. The study also emphasizes ethical standards for early risk disclosure and aims to provide detailed clinical phenotyping, particularly regarding non-motor symptoms. No interventions will be administered, as this is an observational study.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 50 to 99 who are at increased risk for developing Parkinson's Disease but do not currently have the condition.
Not a fit: Patients with existing Parkinson's Disease or significant neurological diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier identification and better management of individuals at risk for Parkinson's Disease.
How similar studies have performed: Other studies have shown promise in identifying risk factors for Parkinson's Disease, but this approach focusing on prodromal screening is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 50 and 99 Exclusion Criteria: * Presence of clinical PD at the time of study inclusion * Other significant neurologic diseases affecting the central nervous system (e.g. Multiple sclerosis) * other significant diseases e.g. orthopaedic diseases affecting quantitative motor assessment * in case of participation in the lumbal puncture substudy: contraindications for the performance of lumbal puncture (bleeding tendency, intake of anticoagulants)
Where this trial is running
Kiel
- Department for Neurology, University of Kiel — Kiel, Germany (Recruiting)
Study contacts
- Principal investigator: Daniela Berg, Prof.Dr. — Department for Neurology, University of Kiel
- Study coordinator: Eva Schaeffer, Dr.
- Email: eva.schaeffer@uksh.de
- Phone: 004943150023983
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.